PharmaKure partners with Sheffield Hallam University to develop epigenetic markers for Alzheimer’s disease prediction

  • Post author:
  • Post category:uncategorized

PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease (AD) and other neurodegenerative diseases, today announces a new epigenetics collaboration with Sheffield Hallam University.